Recently, APLN receptor (APLNR) was considered to be an essential gene for tumor immunotherapy, which can modulate the function of CD8+T cells, but the immunological effects of the APLN/APLNR axis in ccRCC remain unknown (Tolkach et al., 2019). The gene discussed is APLNR; the disease is nonpapillary renal cell carcinoma.